QR Code

Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis

To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based o...

Description complète

Enregistré dans:
Auteurs principaux: Minghui Li, Weihua Cao, Tingting Jiang, Wen Deng, Shiyu Wang, Shuling Wu, Lu Zhang, Yao Lu, Min Chang, Ruyu Liu, Xiaoyan Ding, Ge Shen, Yuanjiao Gao, Hongxiao Hao, Xiaoxue Chen, Leiping Hu, Mengjiao Xu, Yuyong Jiang, Wei Yi, Yao Xie, Rui Song
Format: Artigo
Langue:Inglês
Publié: Elsevier 2024-06-01
Collection:Biosafety and Health
Sujets:
Ursodeoxycholic acid (UDCA)
Autoimmune liver disease (AILD)
Coronavirus disease 2019 (COVID-19)
Primary biliary cholangitis (PBC)
Autoimmune hepatitis (AIH)
Accès en ligne:http://www.sciencedirect.com/science/article/pii/S2590053624000545
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires